肿瘤细胞治疗研究
英文原题：Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-T cells during killing of glioma cells in vitro.
Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-T cells during killing of glioma cells in vitro.
RVG29修饰增强了CAR-T对脑肿瘤的疗效，并有望用于治疗胶质瘤。
CAR-T 细胞疗法由于血脑屏障和T细胞耗竭，在胶质瘤治疗中的疗效有限。使用狂犬病病毒糖蛋白（RVG29）进行增强已显示出改善脑部相关疗效。
在本研究中，我们通过用RVG29修饰抗CD70 CAR-T细胞，开发了CD70R CAR-T细胞，并在体外测试了其杀瘤能力。
通过 RNA-seq 进行的转录组分析揭示了修饰后的 CD70R CAR-T 细胞中激活的信号通路。这些细胞对 CD70+ 胶质瘤细胞表现出有效的体外细胞毒性，此外，与胶质瘤细胞共培养促进了静息 CD70R CAR-T 细胞的扩增。
BACKGROUND: Chimeric antigen receptor T cell therapy has limited efficacy in the treatment of glioma due to the blood-brain barrier and T cell exhaustion. Enhancement with rabies virus glycoprotein (RVG29) has shown improved brain-related efficacy. METHODS: In this study, we developed CD70R CAR-T cells by modifying anti-CD70 CAR-T cells with RVG29 and tested their tumor-killing ability in vitro . RESULTS: Transcriptomic profiling via RNA-seq revealed the activated signaling pathways in modified CD70R CAR-T cells. These cells displayed effective in vitro cytotoxicity against CD70 + ; glioma cells, furthermore, co-culture with glioma cells promoted the expansion of quiescent CD70R CAR-T cells. CONCLUSION: The RVG29 modification enhances CAR-T therapy for brain tumors and holds promise for treating glioma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
